This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAbout AboutWhy PENBRAYA?Risks of Meningococcal DiseaseGaps in Vaccination CoverageDosing & Recommendations Effectiveness & Safety Effectiveness
& Safety ImmunogenicitySafety ProfileIn Your Practice In Your PracticeSimplified CombinationHow to Transition to PENBRAYAPreparing PENBRAYAResources ResourcesRequest a RepresentativeHealth Plan CoverageMaterialsVideos
Prescribing InformationIndicationsPatient SiteRequest a RepLoading
ACIP Recommendation UpdateIn October 2023, the Advisory Committee on Immunization Practices (ACIP) voted on meningococcal vaccination recommendations that are now official and have been adopted by the CDC.1 They have been published in MMWR. Click here for more details.TitleExample TextPENBRAYA is the FIRST and ONLY pentavalent (5-in-1) MenABCWY vaccine1-3Now you can offer the broadest protection against the 5 leading meningococcal serogroups (A, B, C, W, and Y) with the fewest injections1-9*†
Vaccinate your healthy 16-year-old patients with 5-in-1 PENBRAYA1,2
One less injection is needed for healthy adolescents at age 16 to complete the recommended meningococcal vaccination schedule compared to separate MenACWY and MenB vaccines.1,2Based on data in the CDC enhanced meningococcal surveillance reports from 2017 to 2022 for 16- to 23-year-olds. The number of cases for each serogroup were as follows: MenA=0; MenB=120; MenC=20; MenW=5; MenY=9; other/unknown=31; and non-groupable=49.4-9CDC=Centers for Disease Control and Prevention; MMWR=Morbidity and Mortality Weekly Report.Helpful information about getting started with PENBRAYA Why PENBRAYA?

PENBRAYA offers the broadest protection against the 5 leading meningococcal serogroups (A, B, C, W, and Y) in a combination vaccine

LoadingDosing and Recommendations

Learn about ACIP-recommended dosing for PENBRAYA

LoadingSimplified Combination

PENBRAYA can streamline vaccination for your patients and practice 

LoadingMeningococcal disease in the news CDC Health Alert—Increase in Serogroup Y Meningococcal Disease Cases in the United States10

The CDC has issued a health advisory to alert healthcare providers to an increase in serogroup Y meningococcal disease.

The CDC has issued a health advisory to alert healthcare providers to an increase in serogroup Y meningococcal disease.

Distributed via the CDC Health Alert Network
March 28, 2024, 1:30 PM ETDistributed via the CDC Health Alert Network March 28, 2024, 1:30 PM ET Statewide Serogroup Y Outbreak in Virginia11

The Virginia Department of Health is responding to a statewide outbreak of meningococcal disease caused by the bacterium Neisseria meningitidis serogroup Y. 

The Virginia Department of Health is responding to a statewide outbreak of meningococcal disease caused by the bacterium Neisseria meningitidis serogroup Y. 

Distributed by Virginia Department of Health
Last updated April 2, 2024Distributed by Virginia Department of Health Last updated April 2, 2024

References: 1. Collins JP, Crowe JS, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices ― United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350. 2. PENBRAYA [prescribing information]. New York, NY: Pfizer Inc.; 2023. 3. Vaccines and preventable diseases: meningococcal vaccination. Centers for Disease Control and Prevention. Last reviewed November 20, 2023. Accessed January 22, 2024. https://www.cdc.gov/vaccines/vpd/mening/index.html 4. Enhanced meningococcal disease surveillance report, 2017. Centers for Disease Control and Prevention. Accessed June 27, 2024. https://stacks.cdc.gov/view/cdc/75419 5. Enhanced meningococcal disease surveillance report, 2018. Centers for Disease Control and Prevention. Accessed June 27, 2024. https://stacks.cdc.gov/view/cdc/111348​​​​​​​ 6. Enhanced meningococcal disease surveillance report, 2019. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2019.pdf 7. Enhanced meningococcal disease surveillance report, 2020. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2020.pdf 8. Enhanced meningococcal disease surveillance report, 2021. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2021.pdf 9. Enhanced meningococcal disease surveillance report, 2022. Centers for Disease Control and Prevention. Accessed May 6, 2024. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2022-508.pdf 10. Increase in invasive serogroup Y meningococcal disease in the United States. Centers for Disease Control and Prevention. Last reviewed March 28, 2024. Accessed May 3, 2024. https://emergency.cdc.gov/han/2024/han00505.asp 11. Surveillance and investigation: meningococcal disease outbreak response. Virginia Department of Health. Last reviewed Abril 2, 2024. Accessed May 3, 2024. https://www.vdh.virginia.gov/surveillance-and-investigation/meningococcal-disease-outbreak-response/

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-PBI-USA-0339
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
     
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age